NVCR · NovoCure
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $14.17
Note written ·
Price against the kill line
16.5% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $14.17, on record since 10 November 2026. The shares are down 32.5% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $14.17, the close before the results of 29 October 2026 (28 October 2026), would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 29 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 193
- Revenue, change on a year (%)
- +15.7
- Gross margin (%)
- 77.0
- Operating margin (%)
- −3.2
- Free cash flow, four quarters ($M)
- −24.6
- Net cash, cash less debt ($M)
- −102
- Enterprise value to sales (×)
- 2.0
- Free-cash-flow yield (%)
- −1.8
All filed numbers
What NovoCure reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 193 | +15.7 | 77.0 | −3.2 |
| first filed | 184 | +15.6 | 77.6 | −5.8 |
| first filed | 174 | +12.3 | 77.6 | −38.7 |
| first filed | 174 | +8.1 | 75.8 | −23.2 |
| first filed | 167 | +7.8 | 73.2 | −21.5 |
| first filed | 159 | +5.6 | 73.9 | −24.9 |
| Pre-tax income ($M) | −7.9 |
| Net income ($M) four quarters: −122 | −10.4 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +4.4 |
| Operating cash flow ($M) | −0.7 |
| Capital spending ($M) | 23.9 |
| Free cash flow ($M) | −24.6 |
| Cash and short-term investments ($M) | 96.7 |
| Debt ($M) at 30 June 2026, filed 23 July 2026; credit line | 196 |
| Net cash, cash less debt ($M) at 30 June 2026, filed 23 July 2026 | −102 |
| Deferred revenue ($M) +11.6% on a year | 17.5 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 108 |
| Inventory ($M) | 40.6 |
| Shareholders' equity ($M) | 351 |
| Market value ($M) | 1,383 |
| Enterprise value, market value plus net debt ($M) | 1,485 |
| Enterprise value to sales (×) | 2.0 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 3.9 |
| Free-cash-flow yield (%) | −1.8 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 11.0% of shares outstanding sold short, 7.7 days of average trading to cover, +14.9% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $143K |
| 12 monthsfrom | $0 | $3.4M |
The thesis
NovoCure Limited's existing business is growing, but the FDA's 9 November 2026 Not Approvable letter for Optune Mya in brain metastases from non-small cell lung cancer removes the expansion story the shares needed. The adjusted close on 9 November 2026 was $12.53, 37.3% below the 52-week high of $19.99 and 28.8% lower over three months. What settles the case is whether the company's meetings with the FDA produce a route to approval without a new clinical trial.
The company reported third-quarter 2026 results on 29 October 2026. Revenue was $193.399 million against a $182.233 million analyst estimate, and earnings per share were a loss of $0.09 against an expected loss of $0.24 (Benzinga). Full-year revenue guidance rose from $710–725 million to $736–743 million, against a $725.814 million estimate (Benzinga).
The FDA letter came 11 days later. According to press coverage of the company's release, the agency cited uncertainty about the size of the clinical benefit and raised no safety concern. The company said it is meeting the FDA to seek a path that avoids new trials, and that those talks may not lead to approval (Investing.com, GuruFocus, 9 November 2026). The company had hoped for approval by the end of 2026 and a 2027 launch.
The story is well known: the story is well known, the July and October results are now in the price, and the 9 November 2026 letter ended the near-term expansion leg of it. The 14-day Relative Strength Index (RSI), a momentum gauge where readings near 20 mark heavy selling, was 26.0 on 9 November 2026.
Bullish and bearish views on NovoCure Limited
The bull case on NovoCure Limited (NVCR), in brief: core business beat and raised. The bear case: the brain-metastases launch is delayed or lost.
Bull case
- Core business beat and raised. Third-quarter revenue of $193.399 million beat the $182.233 million estimate, and the 2026 outlook rose to $736–743 million (Benzinga, 29 October 2026). Coverage of the release reports adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $15.7 million and a gross margin of 77%, up from 73%.
- Glioblastoma patient growth continues. Press coverage of the release reports about 4,730 active glioblastoma patients, up 11%, and a record patient total (Panabee, 29 October 2026). The company reported 5,128 active patients at 30 June 2026 against 4,331 a year earlier.
- Balance sheet funds the wait. Coverage of the release reports $463.5 million of cash and short-term investments at 30 September 2026. A regulatory delay does not create a near-term funding question on that figure.
- The FDA objection was about benefit, not safety. The company's release, as reported on 9 November 2026, says the agency raised no safety issue. The METIS trial met its primary endpoint, a delay in time to intracranial progression (clinicaltrialsarena).
- Some analysts hold higher targets. Evercore ISI kept Outperform and lowered its target to $20 on 30 October 2026. HC Wainwright's target was $52 on 23 July 2026. A price-target aggregator showed a 12-month target of $22.2 on 5 November 2026.
Bear case
- The brain-metastases launch is delayed or lost. The FDA's Not Approvable letter on 9 November 2026 follows a trial that missed its secondary endpoints of overall survival, neurocognitive failure and radiological response (clinicaltrialsarena). The company has said the FDA talks may not lead to approval.
- Pancreatic uptake is slipping. Coverage of the third-quarter release reports 276 active Optune Pax patients, down from 285 in the second quarter. A Stocktwits headline reports the CEO said Revolution Medicines' daraxonrasib slowed Optune Pax adoption.
- Quality of the quarter is mixed. About $4.4 million of third-quarter revenue came from a one-time benefit tied to higher claims approval rates in the US and Germany (coverage of the 29 October 2026 release). One analysis of the guidance puts implied fourth-quarter revenue near $188.5 million, below the third quarter.
- Analysts cut targets after the beat. Wells Fargo kept Equal-Weight and lowered its target to $15 on 30 October 2026. Evercore ISI lowered its target to $20 the same day.
- Losses persist on a reported basis. The first-half 2026 net loss was $86.8 million and the accumulated deficit was $1,377.2 million at 30 June 2026 (second-quarter filing). The third-quarter net loss narrowed to $10.4 million (coverage of the 29 October 2026 release).
Price setup
The shares closed at $12.53 on 9 November 2026 (adjusted daily closes). That is 37.3% below the 52-week high of $19.99. The close on 27 October 2026 was $14.62, so the shares have fallen from that level despite the third-quarter beat.
The RSI(14) reading of 26.0 shows heavy recent selling; it was 49.7 on 27 October 2026. The 14 October 2026 close of $13.84 is now above the price. The shares were trading near $13.28 intraday on 9 November 2026 according to GuruFocus, so the day closed lower than that.
Crowding evidence is limited. No earnings date falls inside the next 30 days. Selling has been orderly and analyst targets span about 3x, from $15 at Wells Fargo to $52 at HC Wainwright. No retail-attention, insider-selling or share-issuance data point is available for this note.
Catalysts ahead
- TBD (no date set): Outcome of NovoCure's meetings with the FDA on a path to approval for Optune Mya. A path that avoids new trials would keep a 2027 brain-metastases launch alive; a request for new data would end it.
- ~February 2027 (est.): Fourth-quarter and full-year 2026 results. It shows whether revenue holds near the third-quarter level without the $4.4M one-time benefit and sets 2027 guidance without Optune Mya.
What would change the view
A daily close above $14.17, the close before the results of 29 October 2026 (28 October 2026), would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
TTFields is a category of one: no listed peer sells a comparable device, so no sector group confirms or refutes a move in the shares. Oncology drug news can still move the story. Revolution Medicines' daraxonrasib was cited by the CEO as a drag on pancreatic adoption, per a Stocktwits headline. Device-regulatory outcomes at the FDA are the main outside driver of the shares.
The evidence, claim by claim (8)
- Q3 2026 revenue was $193.399M against a $182.233M estimate; EPS was a loss of $0.09 against an expected loss of $0.24. Benzinga, NovoCure Q3 2026 results · as of
- Full-year 2026 revenue guidance raised from $710–725M to $736–743M, against a $725.814M estimate. Benzinga, NovoCure FY2026 guidance · as of
- Q3 adjusted EBITDA was $15.7M, net loss was $10.4M, gross margin was 77%, and cash and short-term investments were $463.5M. Coverage of the NovoCure Q3 2026 release (Panabee) · as of
- About $4.4M of Q3 revenue came from a one-time benefit tied to higher claims approval rates in the US and Germany. Coverage of the NovoCure Q3 2026 release (Panabee) · as of
- FDA issued a Not Approvable letter for Optune Mya in brain metastases from non-small cell lung cancer, citing uncertain clinical benefit; no safety concern was raised. Investing.com; GuruFocus; NovoCure regulatory update · as of
- Optune Pax active patients were 276 at the end of Q3, down from 285 in Q2 (one source reports 266 US-only). Coverage of the NovoCure Q3 2026 release · as of
- Wells Fargo kept Equal-Weight and cut its target to $15; Evercore ISI kept Outperform and cut its target to $20. Benzinga analyst notes · as of
- Adjusted close was $12.53 on 9 November 2026, 37.3% below the 52-week high of $19.99; RSI(14) was 26.0. Split/dividend-adjusted daily closes · as of
Sources
- FDA Issues Not Approvable Letter for Novocure's Optune Mya, NVCR Stock Reacts · gurufocus.com
- Novocure receives FDA rejection for brain cancer treatment · investing.com
- Novocure Stock Slips After FDA Rejects Its Cancer Treatment Device · benzinga.com
- NovoCure Raises 2026 Guidance as Active Patient Volume Climbs 19% · panabee.com
- NovoCure Ltd - Form 8-K - FY2026 · sec.gov
- Stocktwits
- Clinical Trials Arena
Related · shared themes
JNJ
Johnson & Johnson
Johnson & Johnson's drug approvals keep coming, but weak medical devices and $1.36 per share of 2027 deal dilution leave the shares more…
GH
Guardant Health
Guardant Health's Shield revenue is growing fast, but patent losses, wider cash-burn guidance and a new $500 million convertible note sale…
CDNA
CareDx
CareDx's shares are modestly more likely than not to beat the S&P 500: transplant testing revenue grew 39% in the third quarter excluding…
ORKA
Oruka Therapeutics
Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely…
See also · stocks to watch